中外医疗
中外醫療
중외의료
CHINA FOREIGN MEDICAL TREATMENT
2015年
16期
91-92
,共2页
急性心肌梗死%心力衰竭%重组人脑利钠肽%循环内分泌%影响
急性心肌梗死%心力衰竭%重組人腦利鈉肽%循環內分泌%影響
급성심기경사%심력쇠갈%중조인뇌리납태%순배내분비%영향
Acute Myocardial Infarction%Heart failure%Brain natriuretic peptide%Circulation endocrine%Effects
目的：探讨分析重组人脑利钠肽对于AMI心力衰竭患者循环内分泌的影响。方法整群选取该院2013年7月-2014年7月收治的68例AMI心力衰竭患者，将其分为观察组(34例)和对照组(34例)，给予观察组患者常规治疗的基础上静脉注射重组人脑利钠肽。对比两组患者心力衰竭情况、LVEF、PRA、ALD和ATⅡ等指标。结果经治疗，两组LVEF均有心力衰竭缓解程度提高，其中观察组LVEF的提高优于治疗前和对照组，两组差异有统计学意义(P<0.05)。两组患者治疗前后的PRA、ALD、ATⅡ变化差异对比有意义(P<0.05)，其中观察组整体下降程度优于对照组，两组差异有统计学意义(P<0.05)。结论对AMI心力衰竭患者运用重组人脑利钠肽有较高的临床治疗效果，改善患者心室功能，对患者的循环内分泌系统功能的恢复有着积极的促进作用，值得临床推广和应用。
目的：探討分析重組人腦利鈉肽對于AMI心力衰竭患者循環內分泌的影響。方法整群選取該院2013年7月-2014年7月收治的68例AMI心力衰竭患者，將其分為觀察組(34例)和對照組(34例)，給予觀察組患者常規治療的基礎上靜脈註射重組人腦利鈉肽。對比兩組患者心力衰竭情況、LVEF、PRA、ALD和ATⅡ等指標。結果經治療，兩組LVEF均有心力衰竭緩解程度提高，其中觀察組LVEF的提高優于治療前和對照組，兩組差異有統計學意義(P<0.05)。兩組患者治療前後的PRA、ALD、ATⅡ變化差異對比有意義(P<0.05)，其中觀察組整體下降程度優于對照組，兩組差異有統計學意義(P<0.05)。結論對AMI心力衰竭患者運用重組人腦利鈉肽有較高的臨床治療效果，改善患者心室功能，對患者的循環內分泌繫統功能的恢複有著積極的促進作用，值得臨床推廣和應用。
목적：탐토분석중조인뇌리납태대우AMI심력쇠갈환자순배내분비적영향。방법정군선취해원2013년7월-2014년7월수치적68례AMI심력쇠갈환자，장기분위관찰조(34례)화대조조(34례)，급여관찰조환자상규치료적기출상정맥주사중조인뇌리납태。대비량조환자심력쇠갈정황、LVEF、PRA、ALD화ATⅡ등지표。결과경치료，량조LVEF균유심력쇠갈완해정도제고，기중관찰조LVEF적제고우우치료전화대조조，량조차이유통계학의의(P<0.05)。량조환자치료전후적PRA、ALD、ATⅡ변화차이대비유의의(P<0.05)，기중관찰조정체하강정도우우대조조，량조차이유통계학의의(P<0.05)。결론대AMI심력쇠갈환자운용중조인뇌리납태유교고적림상치료효과，개선환자심실공능，대환자적순배내분비계통공능적회복유착적겁적촉진작용，치득림상추엄화응용。
Objective To investigate the effects of recombinant human brain natriuretic peptide on circular endocrine in patients with heart failure caused by AMI. Methods 68 cases of heart failure in patients with AMI admitted to our hospital in July 2013 to July 2014 year were selected and divided into observation group (34 cases) and control group (34 cases). Patients in observation group were given intravenous recombinant human brain natriuretic peptide treatment based on routine treatment. Indexes including heart failure, LVEF, PRA, ALD and AT II were compared between the two groups. Results After treatment, two groups of LVEF were relieved degree of heart failure increased, which improved better than the treatment observation group before LVEF and control group, compared two groups of significant differences (P<0.05). The two groups before and after treatment in patients with PRA, ALD, AT II changes in contrast differences significant (P<0.05), the overall decline in the degree of the observation group than the control group, compared two groups of significant differences (P<0.05). Conclusion The clinical treatment effect of AMI in patients with heart failure with recombinant human brain natriuretic peptide has higher, improve cardiac function in patients with, have positive effects on circulation function of patients with endocrine system recovery, is worthy of promotion and application.
